Investigation of CYP2D6 (*2,*3,*4,*7,*10,*41) gene polymorphisms in pediatric cardiology patients
Abstract views: 90
/ 
PDF downloads: 36
DOI:
https://doi.org/10.26900/hsq.2837Keywords:
Pharmacogenetics, CYP2D6 genetic polymorphism, pediatric cardiac patientsAbstract
The CYP2D6 enzyme metabolizes several antiarrhythmic, antihypertensive drugs, especially beta-blockers. CYP2D6 genetic polymorphisms can change the efficacy and toxicity of these cardiac drugs. On the other hand, in pediatric cardiac patients, the practical significance of CYP2D6 genetic polymorphisms studied only in a few studies. This study aimed to evaluate CYP2D6 gene polymorphisms (*2, *3, *4, *7, *10 and *41) in these patients, prospectively. Blood samples (2 ml) were taken from 200 patients who applied to Afyonkarahisar Health Sciences University, Faculty of Medicine, Pediatric Cardiology Clinic. CYP2D6 enzyme gene polymorphisms (*2, *3, *4, *7, *10, and *41) were determined by using Polymerase Chain Reaction (PCR) amplification DNA Sequence Analysis methods. We found that 81.5% of the cases were normal metabolizers (NM), 16% were intermediate metabolizers (IM), and 2.5% were poor metabolizers (PM). The most common alleles were found to be *1 (61.75%), *2 (11%), *3 (10.75%), and *10 (10.25%), respectively. Of the 5 patients using beta-blockers and risperidone, 4 were found to be NM and 1 was IM. No changes in drug doses were required. The CYP2D6*3 allele with loss of enzyme function was determined as the most common mutant allele in this study. However, the frequency distributions of the PM (2.50%) and IM (16%) phenotypes in our study population differed markedly from the frequency distributions of the PM (7.5%) and IM (6%) phenotypes observed in the Caucasian population (p<0.02). The fact is that 18.5% of the cases in which changes in enzyme activity were detected in our study. It would be beneficial in terms of determining CYP2D6 gene changes in pediatric cardiac patients before treatment.
Downloads
References
Taylor C, Crosby I, Yip V, Maguire P, Pirmohamed M, Turner RM. Genes (Basel). A Review of the important role of CYP2D6 in pharmacogenomics. 2020;11(11):1295. doi: 10.3390/genes11111295. DOI: https://doi.org/10.3390/genes11111295
Zhou SF. Polymorphism of human cytochrome P450 2D6 and its clinical significance: Part I. Clin Pharmacokinet. 2009;48(11):689-723. doi: 10.2165/11318030-000000000-00000. DOI: https://doi.org/10.2165/11318030-000000000-00000
Sobrino B, Brion M, Carracedo A. SNPs in forensic genetics: A review on SNP typing methodologies. Forensic Sci Int. 2005;154 (2-3):181-94. doi: 10.1016/j.forsciint.2004.10.020. DOI: https://doi.org/10.1016/j.forsciint.2004.10.020
Just KS, Schneider KL, Schurig M, Stingl JC, Brockmöller J. Falls: The adverse drug reaction of the elderly and the impact of pharmacogenetics. Pharmacogenomics. 2017;18(13):1281-97. doi: 10.2217/pgs-2017-0018. DOI: https://doi.org/10.2217/pgs-2017-0018
Marez D, Legrand M, Sabbagh N, Lo Guidice JM, Spire C, Lafitte JJ, et al. Polymorphism of the cytochrome P450 CYP2D6 gene in a European population: Characterization of 48 mutations and 53 alleles, their frequencies and evolution. Pharmacogenetics. 1997;7(3):193-202. doi: 10.1097/00008571-199706000-00004. DOI: https://doi.org/10.1097/00008571-199706000-00004
Nahid NA, Johnson JA. CYP2D6 pharmacogenetics and phenoconversion in personalized medicine. Expert Opin Drug Metab Toxicol. 2022;18(11):769-85. doi: 10.1080/17425255.2022.2160317. DOI: https://doi.org/10.1080/17425255.2022.2160317
Sachse C, Brockmoller J, Bauer S, Roots I. Cytochrome P450 2D6 variants in a Caucasian population: Allele frequencies and phenotypic consequences. Am J Hum Genet. 1997;60(2):284-95.
Roberts RL and Kennedy MA. Rapid detection of common cytochrome P450 2D6 alleles in Caucasians. Clinica Chimica Acta. 2006;366(1-2):348-51. doi: 10.1016/j.cca.2005.11.008. DOI: https://doi.org/10.1016/j.cca.2005.11.008
Daly AK. Pharmacogenetics of drug metabolizing enzymes in the United Kingdom population: Review of current knowledge and comparison with selected European populations. Drug Metab Pers Ther. 2015;30(3):165-74. doi: 10.1515/dmdi-2014-0034. DOI: https://doi.org/10.1515/dmdi-2014-0034
Ingelman-Sundberg M. Genetic polymorphisms of cytochrome P4502D6 (CYP2D6): Clinical consequences, evolutionary aspects and functional diversity. Pharmacogenomics J. 2005;5(1):6-13. doi: 10.1038/sj.tpj.6500285. DOI: https://doi.org/10.1038/sj.tpj.6500285
Haertter S. Recent examples on the clinical relevance of the CYP2D6 polymorphism and endogenous functionality of CYP2D6. Drug Metabol Drug Interact. 2013;28(4):209-16. doi: 10.1515/dmdi-2013-0032. DOI: https://doi.org/10.1515/dmdi-2013-0032
Wall CA, Croarkin PE, Swintak C, Koplin BA. Psychiatric pharmacogenomics in pediatric psychopharmacology. Child Adolesc Psychiatr Clin N Am. 2012;21(4):773-88. doi: 10.1016/j.chc.2012.07.001. DOI: https://doi.org/10.1016/j.chc.2012.07.001
Kirchheiner J, Nickchen K, Bauer M, Wong M-L, Licinio J, Roots I, et al. Pharmacogenetics of antipsychotics: The contribution of alelic variations to the phenotype of drug response. Mol Psychiatry. 2004;9(5):442-73. doi: 10.1038/sj.mp.4001494. DOI: https://doi.org/10.1038/sj.mp.4001494
Aynacioglu AS, Sachse C, Bozkurt A, Kortunay S, Nacak M, Schröder T. et al. Low frequency of defective aleles of cytochrome P450 enzymes 2C19 and 2D6 in the Turkish population. Clin Pharmacol Ther. 1999; 66(2):185-92. doi: 10.1053/cp.1999.v66.100072001. DOI: https://doi.org/10.1053/cp.1999.v66.100072001
Ingelman-Sundberg M. Implications of polymorphic cytochrome p450- dependent drug metabolism for drug development. Drug Metab Dispos. 2001;29:570-3.
Poh BH, Lee JH, Abdul Haium AA, Choo TLJ. Complete heart block secondary to Flecainide Toxicity: Is it time for CYP2D6 genotype testing? – A case report. Pediatrics. 2020;146(1):e20192608. doi: 10.1542/peds.2019-2608. DOI: https://doi.org/10.1542/peds.2019-2608
Sunthankar SD, Kannankeril PJ, Gaedigk A, Radbil AE, Fish FA, Driest SLV. Influence of CYP2D6 genetic variation on adverse events with propafenone in the pediatric and young adult population. Clin Transl Sci. 2022;15(7):1787-95. doi: 10.1111/cts.13296. DOI: https://doi.org/10.1111/cts.13296
Moric-Janiszewska E, Smolik S, Szydłowski L, Kapral M. Associations between selected ADRB1 and CYP2D6 gene polymorphisms in children with ventricular and supraventricular arrhythmias. Medicina (Kaunas). 2023;59(12):2057.doi: 10.3390/medicina59122057. DOI: https://doi.org/10.3390/medicina59122057
Taşkin B, Percin FE, Ergun MA, Investigation of CYP2D6 gene polymorphisms in Turkish population. Psychopharmacol Bull.2016;46(1):67-72.
Serin A, Canan H, Alper B, Gulmen M. The frequencies of mutated aleles of CYP2D6 gene in a Turkish population. Forensic Sci Int. 2012;222(1-3):332-4. doi: 10.1016/j.forsciint.2012.07.012. DOI: https://doi.org/10.1016/j.forsciint.2012.07.012
Teh LK, Zilfalil BA, Marina I, Rosemi BS, Ismail R. Genetic polymorphism of CYP2D6 in patients with cardiovasculer disease – A cohort study. J Clin Pharm Ther. 2004;9(6):559-64. doi: 10.1111/j.1365-2710.2004.00600.x. DOI: https://doi.org/10.1111/j.1365-2710.2004.00600.x
Fux R, Mörike K, Pröhmer AM, Delabar U, Schwab M, Schaeffeler E, et al. Impact of CYP2D6 genotype on adverse effects during treatment with metoprolol: A prospective clinical study. Clin Pharmacol Ther. 2005;78(4):378-87. doi: 10.1016/j.clpt.2005.07.004. DOI: https://doi.org/10.1016/j.clpt.2005.07.004
Wu D, Li G, Deng M, Song W, Huang X, Guo X, et al. Associations between ADRB1 and CYP2D6 gene polymorphisms and the response to β-blocker therapy in hypertension. J Int Med Res. 2015;43(3):424-34. doi: 10.1177/0300060514563151. DOI: https://doi.org/10.1177/0300060514563151
Meloche M, Khazaka M, Kassem I, Barhdadi A, Dubé M-P, de Denus S. CYP2D6 polymorphism and its impact on the clinical response to metoprolol: A systematic review and meta-analysis. Br J Clin Pharmacol. 2020;86(6):1015-33. doi: 10.1111/bcp.14247. DOI: https://doi.org/10.1111/bcp.14247
Zoghi M, Kaya H, Çavuşoğlu Y, Aksakal E, Demir S, Yücel C, et.al. Frequency of genetic polymorphism for adrenergic receptor beta and cytochrome p450 2D6 enzyme, and effects on tolerability of beta-blocker therapy in heart failure with reduced ejection fraction patients: The Beta GenTURK study. Turk Kardiyol Dern Ars. 2016;44(6):457-65. doi: 10.5543/tkda.2016.10733. DOI: https://doi.org/10.5543/tkda.2016.10733
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Holistence Publications
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
1. Authors retain copyright and grant the journal right of first publication, with the work simultaneously licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0) that allows others to share and adapt the work with an acknowledgement of the work's authorship and initial publication in this journal.
2. Everyone who is listed as an author in this article should have made a substantial, direct, intellectual contribution to the work and should take public responsibility for it.
